Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

European archives of psychiatry and clinical neuroscience - 1 Aug 2006

Thuerauf Norbert, Lunkenheimer Jens

Abstract excerpt

Cytochrome P450 CYP2D6 represents an extensively characterized polymorphic drug-metabolizing enzyme. The CYP2D6-gene is highly polymorphic and more than 70 different alleles are known currently. The activity of the enzyme markedly varies among individuals from poor to intermediate and extensive up to ultrarapid metabolism on the basis of the polymorphism of the CYP2D6 gene. Association studies provide growing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Genotype

Share to Mixed Function Oxygenases

Share to Pharmaceutical Preparations

Share to Polymorphism, Genetic

Share to Substrate Specificity

Source

Identifiers

PMID: 16783493
DOI: 10.1007/s00406-006-0663-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.PMID 16783493Read ↗

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Semantic proximity Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

[Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].Semantic proximity Read ↗

Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.Semantic proximity Read ↗

The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.Semantic proximity Read ↗

Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.Semantic proximity Read ↗

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.Semantic proximity Read ↗

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.Semantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.